• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23886 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine formulations for opioid use disorder
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic drugs for severe asthma
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aging in place
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Renal sympathetic denervation for the management of resistant hypertension]
2024     Scottish Health Technologies Group (SHTG) Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack (TIA) - SHTG Assessment
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of deep brain stimulation in severe and treatment-resistant obsessive-compulsive disorder]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula. Update]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Exposure therapy with virtual reality in adults with specific phobia]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and effectiveness of non-invasive management of pectus excavatum with vacuum bell therapy]
2024     Ontario Health Interferon-gamma release assay testing for latent tuberculosis infection: a health technology assessment
2024     Ontario Health Single-exposure, dual-energy subtraction flat panel x-ray detectors: a health technology assessment
2024     Ontario Health Peripheral nerve stimulation for chronic neuropathic pain: a health technology assessment
2024     Ontario Health Plasma-based comprehensive genomic profiling DNA assays for non–small cell lung cancer: a health technology assessment
2024     Ontario Health Pelvic floor muscle training for stress urinary incontinence, fecal incontinence, and pelvic organ prolapse: a health technology assessment
2024     Ontario Health Fractional exhaled nitric oxide testing for the diagnosis and management of asthma: a health technology assessment
2024     Ontario Health Sucrose octosulfate (SOS)-impregnated dressings for adults with difficult-to-heal noninfected diabetic foot ulcers and difficult-to-heal noninfected venous leg ulcers
2024     Ontario Health Level 2 polysomnography for the diagnosis of sleep disorders: a health technology assessment
2024     Ontario Health Intrathecal drug delivery systems for cancer pain
2024     Ontario Health Minimally invasive bleb surgery for glaucoma: a health technology assessment
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post covid and other post infectious diseases]
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Indicated prevention of suicide in children and adolescents]
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Liquid biopsy in the diagnosis of ovarian cancer – a compilation of scientific literature]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted prostatectomy for prostate cancer: A health technology assessment]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted rectal resection for rectal cancer: A health technology assessment]
2024     Norwegian Institute of Public Health (NIPH) [Robot assisted hysterectomy: A health technology assessment]
2024     Scottish Health Technologies Group (SHTG) Living Donor Transplantation - SHTG Assessment
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety of non-reabsorbable clips in living donor laparoscopic nephrectomy]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal pharmacotherapy for transplant ineligible multiple myeloma
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Adaptive deep brain stimulation in Parkinson's disease]
2024     NIHR Health Technology Assessment programme Cost-effectiveness of bioimpedance-guided fluid management in patients undergoing haemodialysis: the BISTRO RCT
2024     NIHR Health Technology Assessment programme Laparoscopic cholecystectomy versus conservative management for adults with uncomplicated symptomatic gallstones: the C-GALL RCT
2024     NIHR Health Technology Assessment programme Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT
2024     NIHR Health Technology Assessment programme A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation
2024     NIHR Health Technology Assessment programme The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024     NIHR Health Technology Assessment programme Cerclage suture type to prevent pregnancy loss in women requiring a vaginal cervical cerclage: the C-STICH RCT
2024     NIHR Health Technology Assessment programme Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
2024     NIHR Health Technology Assessment programme Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT
2024     NIHR Health Technology Assessment programme Linkage of routinely collected NHS data to evaluate liaison mental health services: challenges and lessons learned
2024     NIHR Health Technology Assessment programme Infliximab versus alpha interferon in the treatment of Behçet’s disease: the BIO BEHÇET’S RCT
2024     NIHR Health Technology Assessment programme Development and evaluation of machine-learning methods in whole-body magnetic resonance imaging with diffusion weighted imaging for staging of patients with cancer: the MALIBO diagnostic test accuracy study
2024     NIHR Health Technology Assessment programme Bezafibrate as treatment in males for Barth syndrome: CARDIOMAN, a double-blind, placebo-controlled crossover RCT
2024     NIHR Health Technology Assessment programme Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT
2024     NIHR Health Technology Assessment programme Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study
2024     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation
2024     NIHR Health Technology Assessment programme Clinical outcomes and adverse events of bariatric surgery in adults with severe obesity in Scotland: the SCOTS observational cohort study
2024     NIHR Health Technology Assessment programme Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
2024     NIHR Health Technology Assessment programme Randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus - BOSS (Barrett's Oesophagus Surveillance Study)
2024     NIHR Health Technology Assessment programme Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
2023     National Institute for Health and Care Excellence (NICE) Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. NICE highly specialised technologies guidance 22
2023     National Institute for Health and Care Excellence (NICE) Asfotase alfa for treating paediatric-onset hypophosphatasia. NICE highly specialised technologies guidance 23
2023     National Institute for Health and Care Excellence (NICE) Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy. NICE highly specialised technologies guidance 24
2023     National Institute for Health and Care Excellence (NICE) Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency. NICE highly specialised technologies guidance 26
2023     National Institute for Health and Care Excellence (NICE) Lumasiran for treating primary hyperoxaluria type 1. NICE highly specialised technologies guidance 25
2023     National Institute for Health and Care Excellence (NICE) Afamelanotide for treating erythropoietic protoporphyria. NICE highly specialised technologies guidance 27
2023     National Institute for Health and Care Excellence (NICE) Birch bark extract for treating epidermolysis bullosa. NICE highly specialised technologies guidance 28
2023     National Institute for Health and Care Excellence (NICE) Velmanase alfa for treating alpha-mannosidosis. NICE highly specialised technologies guidance 29
2023     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Support for the implementation of new ways of working at the Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale]
2023     Haute Autorite de sante (HAS) [Comparative genomic hybridization array (CGHA) analysis in postnatal context]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV) – exagamglogene autotemcel (sickle cell disease)]
2023     Institute for Clinical and Economic Review (ICER) Atidarsagene autotemcel for metachromatic leukodystrophy
2023     Institute for Clinical and Economic Review (ICER) Gene therapies for sickle cell disease
2023     Institute for Clinical and Economic Review (ICER) Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH)
2023     Institute for Clinical and Economic Review (ICER) Lecanemab for early Alzheimer’s disease
2023     Institute for Clinical and Economic Review (ICER) Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of early intervention programs in psychosis targeting adolescents and young adults]
2023     Norwegian Institute of Public Health (NIPH) Stockholm3 test to estimate the risk of prostate cancer: a single technology assessment
2023     Norwegian Institute of Public Health (NIPH) Transcutaneous non-invasive vagus nerve stimulation (gammaCore) for the treatment of cluster headache: A single technology assessment
2023     Haute Autorite de sante (HAS) [Transcutaneous ultrasound-guided intravenous radiofrequency occlusion of the small saphenous vein]
2023     Health Information and Quality Authority (HIQA) Review of national public health strategies in selected countries
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (paroxysmal nocturnal haemoglobinuria); assessment according to §35a Social Code Book V; search for disease registries]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Endobronchial ultrasonography in malignant and benign pulmonary pathology: linear and radial ultrasound-guided transbronchial needle aspiration: evaluation of safety, efficacy, and cost-effectiveness]
2023     WorkSafeBC Cryoneurolysis for shoulder pain
2023     Canary Health Service [Conduction system pacing implantation through electroanatomical mapping-guided vs. fluoroscopy]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy –Third addendum to Commission E16-03]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – Valoctocogen roxaparvovec: review of the study protocol (version 2.0) and the statistical analysis plan (version 2.0) – 3. Addendum to project A22-20]
2023     Canary Health Service [Cost-effectiveness of childhood vaccination against invasive meningococcal disease due to ACWY serogroups]
2023     Canary Health Service [Determination by chemiluminescence of autoantibodies to domain 1 of beta 2 glycoprotein I in patients with antiphospholipid syndrome]
2023     Canary Health Service [Neuropsychological rehabilitation in people with paediatric cancer]
2023     Canary Health Service [Cost-effectiveness of systematic vaccination against invasive meningococcal disease due to serogroup B in childhood]
2023     Canary Health Service [Melanoma detection without biopsy using a non-invasive adhesive patch]
2023     Canary Health Service [Effectiveness, safety and cost-effectiveness of real time continuous glucose monitoring systems, open-loop systems and hybrid closed-loop systems (artificial pancreas) for patients with diabetes]
2023     Canary Health Service [Clinical effectiveness and cost-effectiveness of the extension of colorectal cancer screening up to 74 years of age in general population]
2023     Canary Health Service [Intraoperative radiotherapy in resectable brain tumors and metastases]
2023     Canary Health Service [Genicular artery embolization for the treatment of knee osteoarthritis]
2023     Canary Health Service [Targeted muscle reinnervation in individuals with amputated limbs]
2023     Canary Health Service [Transcranial direct current stimulation device for the treatment of drug-resistant epilepsy]
2023     Canary Health Service [Software to support decisions for the administration of medicines in neonatal and paediatric intensive care units]
2023     National Institute for Health and Care Excellence (NICE) MRI-based technologies for assessing non-alcoholic fatty liver disease. NICE diagnostics guidance 50
2023     National Institute for Health and Care Excellence (NICE) MRI fusion biopsy systems for diagnosing prostate cancer. NICE diagnostics guidance 53
2023     National Institute for Health and Care Excellence (NICE) Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers. NICE diagnostics guidance 52
2023     National Institute for Health and Care Excellence (NICE) Transperineal biopsy for diagnosing prostate cancer. NICE diagnostics guidance 54
2023     National Institute for Health and Care Excellence (NICE) FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. NICE diagnostics guidance 48
2023     National Institute for Health and Care Excellence (NICE) AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images. NICE diagnostics guidance 55
2023     National Institute for Health and Care Excellence (NICE) Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. NICE diagnostics guidance 56
2023     National Institute for Health and Care Excellence (NICE) Devices for remote monitoring of Parkinson's disease. NICE diagnostics guidance 51